N-(Methoxyoxoacetyl)-glycine methyl ester, Dimethyloxalylglycine, HIF Prolyl Hydroxylase Inhibitor I, HIF Aspartyl β-Hydroxylase Inhibitor, HIF Asparanginyl β-Hydroxylase Inhibitor

产品名称：

89464-63-1
HIF-Hydroxylase Inhibitor, DMOG-CAS 89464-63-1-Calbiochem
N-(Methoxyoxoacetyl)-glycine methyl ester, Dimethyloxalylglycine, HIF Prolyl Hydroxylase Inhibitor I, HIF Aspartyl β-Hydroxylase Inhibitor, HIF Asparanginyl β-Hydroxylase Inhibitor

产品介绍：

产品说明

一般描述

A cell-permeable 2-OG (2-oxoglutarate) analog that is expected to act as a competitive inhibitor against all 2-OG-dependent dioxygenases. Effectively upregulates normoxia HIF-α transcription activity (effective conc. = 1 mM in cultures) by inhibiting HIF-PH- (HIF-α-prolyl hydroxylase) catalyzed ODD (oxygen-dependent degradation domain) Prolyl hydroxylation (Pro⁵⁶⁴ and Pro⁵³⁰ in HIF-1α and HIF-2α, respectively) and aspartyl/asparanginyl β-hydroxylase-catalyzed CAD Asp hydroxylation (Asn⁸⁰³ and Asn⁸⁵¹ in HIF-1α and HIF-2α, respectively), resulting in a blockage of pVHL (von Hippel-Lindau) ubiquitin ligase complex-mediated HIF-α degradation and a simultaneous promotion of HIF CAD (COOH-terminal activation domain) p300/CBP association. DMOG is also demonstrated to augment artery ligation-induced up-regulation of HIF-1α and FLK (by 100% and 40%, respectively, in 11 days; 8 mg/0.5 ml/animal/i.p.; q.o.d.) in muscle tissues in a murine ischaemic model in vivo.
A cell-permeable 2-OG (2-oxoglutarate) analog that is expected to act as a competitive inhibitor against all 2-OG-dependent dioxygenases. Effectively upregulates normoxia HIF-α transcription activity (effective conc. = 1 mM in cultures) by inhibiting HIF-PH- (HIF-α-prolyl hydroxylase) catalyzed ODD (oxygen-dependent degradation domain) Prolyl hydroxylation (Pro⁵⁶⁴ and Pro⁵³⁰ in HIF-1α and HIF-2α, respectively) and aspartyl/asparanginyl β-hydroxylase-catalyzed CAD Asp hydroxylation (Asn⁸⁰³ and Asn⁸⁵¹ in HIF-1α and HIF-2α, respectively), resulting in a blockage of pVHL (von Hippel-Lindau) ubiquitin ligase complex-mediated HIF-α degradation and a simultaneous promotion of HIF CAD (COOH-terminal activation domain) p300/CBP association. DMOG is also demonstrated to augment artery ligation-induced up-regulation of HIF-1α and FLK (by 100% and 40%, respectively, in 11 days; 8 mg/0.5 ml/animal/i.p.; q.o.d.) in muscle tissues in a murine ischaemic model in vivo.

包装

50 mg in Glass bottle

警告

Toxicity: Standard Handling (A)

重悬

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

其他说明

Pollard, P.J., et al. 2008. Biochem. J.416, 387.
Chen, H., et al. 2006. Cancer Res.66, 9009.
Milkiewicz, M., et al. 2004. J. Physiol.560, 21.
Lando, D., et al. 2002. Science295, 858.
Jaakkola, P., et al. 2001. Science292, 468.

法律信息

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

基本信息

经验(实验)分子式	C₆H₉NO₅
分子量	175.14
MDL编号	MFCD05865098
NACRES	NA.77

产品性质

质量水平	100
测定	≥98% (HPLC)
manufacturer/tradename	Calbiochem^®
储存条件	OK to freeze desiccated (hygroscopic)
颜色	pink-white to peach-white
溶解性	DMSO: 50 mg/mL
运输	ambient
储存温度	2-8℃
InChI	1S/C6H9NO5/c1-11-4(8)3-7-5(9)6(10)12-2/h3H2,1-2H3,(H,7,9)
InChI key	BNJOZDZCRHCODO-UHFFFAOYSA-N

安全信息

象形图
警示用语：	Warning
危险声明	H302
预防措施声明	P264 - P270 - P301 + P312 - P501
危险分类	Acute Tox. 4 Oral
储存分类代码	11 - Combustible Solids
WGK	WGK 3
闪点(F)	Not applicable
闪点(C)	Not applicable